BNP Paribas Financial Markets Acquires Shares of 104,001 Health Catalyst, Inc. (NASDAQ:HCAT)

BNP Paribas Financial Markets purchased a new stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 104,001 shares of the company's stock, valued at approximately $735,000. BNP Paribas Financial Markets owned about 0.17% of Health Catalyst as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HCAT. Two Sigma Securities LLC raised its holdings in Health Catalyst by 19.5% in the 4th quarter. Two Sigma Securities LLC now owns 17,510 shares of the company's stock valued at $124,000 after buying an additional 2,862 shares during the period. Legato Capital Management LLC increased its position in shares of Health Catalyst by 3.7% during the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company's stock valued at $622,000 after acquiring an additional 3,171 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Health Catalyst in the 4th quarter valued at approximately $29,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Health Catalyst by 8.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company's stock worth $442,000 after acquiring an additional 4,798 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Health Catalyst by 21.7% in the 4th quarter. SG Americas Securities LLC now owns 27,382 shares of the company's stock worth $194,000 after acquiring an additional 4,874 shares during the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Health Catalyst

In other news, COO Daniel Lesueur sold 16,902 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total transaction of $76,397.04. Following the sale, the chief operating officer now owns 216,250 shares of the company's stock, valued at approximately $977,450. This trade represents a 7.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Benjamin Landry sold 13,827 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the transaction, the general counsel now directly owns 160,437 shares of the company's stock, valued at $729,988.35. This trade represents a 7.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 41,147 shares of company stock valued at $182,284. Insiders own 2.50% of the company's stock.

Health Catalyst Stock Up 4.7%

Shares of HCAT stock traded up $0.17 during trading hours on Tuesday, reaching $3.82. 224,458 shares of the stock were exchanged, compared to its average volume of 597,725. The business's fifty day moving average is $4.06 and its two-hundred day moving average is $5.60. The firm has a market capitalization of $265.88 million, a P/E ratio of -2.83 and a beta of 1.56. Health Catalyst, Inc. has a 12-month low of $3.54 and a 12-month high of $9.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Royal Bank of Canada cut their target price on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 27th. Citigroup cut their price objective on Health Catalyst from $7.00 to $6.50 and set a "buy" rating on the stock in a report on Friday, April 25th. Stifel Nicolaus raised their target price on Health Catalyst from $5.00 to $5.50 and gave the company a "hold" rating in a report on Thursday, May 8th. Canaccord Genuity Group dropped their target price on Health Catalyst from $10.00 to $9.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, KeyCorp cut their price target on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $8.00.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.